Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab
Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment. Denosumab, an inhibitor of the RANK ligand involved i...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/767198 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564316269707264 |
|---|---|
| author | Cory Julian Broehm Erika L. Garbrecht Jeff Wood Therese Bocklage |
| author_facet | Cory Julian Broehm Erika L. Garbrecht Jeff Wood Therese Bocklage |
| author_sort | Cory Julian Broehm |
| collection | DOAJ |
| description | Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment. Denosumab, an inhibitor of the RANK ligand involved in bone resorption in GCT, is increasingly used in treatment of recurrent or unresectable giant cell tumor of bone. We report two cases of sarcomatous transformation of GCT to osteosarcoma in patients receiving denosumab. One was a 59-year-old male with a 12-year history of GCT and multiple recurrences taking denosumab for 2.5 years. The second case was in a 56-year-old male with a seven-year history of GCT taking denosumab for six months. Review of the literature shows one case report of malignant transformation of GCT in a patient being treated with denosumab. As the use of denosumab for treatment of GCT will likely increase, larger, controlled studies are needed to ascertain whether denosumab may play a role in malignant transformation of giant cell tumor of bone. |
| format | Article |
| id | doaj-art-27b57f6b94fa46bab3449a0d26c14b3a |
| institution | Kabale University |
| issn | 1687-9627 1687-9635 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Medicine |
| spelling | doaj-art-27b57f6b94fa46bab3449a0d26c14b3a2025-02-03T01:11:18ZengWileyCase Reports in Medicine1687-96271687-96352015-01-01201510.1155/2015/767198767198Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with DenosumabCory Julian Broehm0Erika L. Garbrecht1Jeff Wood2Therese Bocklage3Department of Pathology, University of New Mexico School of Medicine, MSC08 4640, 1 University of New Mexico, Albuquerque, NM 87131, USADepartment of Orthopaedics, University of New Mexico School of Medicine, MSC10 5600, Albuquerque, NM 87131, USADepartment of Radiology, University of New Mexico School of Medicine, MSC10 5530, 1 University of New Mexico, Albuquerque, NM 87131, USADepartment of Pathology, University of New Mexico School of Medicine, MSC08 4640, 1 University of New Mexico, Albuquerque, NM 87131, USAGiant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment. Denosumab, an inhibitor of the RANK ligand involved in bone resorption in GCT, is increasingly used in treatment of recurrent or unresectable giant cell tumor of bone. We report two cases of sarcomatous transformation of GCT to osteosarcoma in patients receiving denosumab. One was a 59-year-old male with a 12-year history of GCT and multiple recurrences taking denosumab for 2.5 years. The second case was in a 56-year-old male with a seven-year history of GCT taking denosumab for six months. Review of the literature shows one case report of malignant transformation of GCT in a patient being treated with denosumab. As the use of denosumab for treatment of GCT will likely increase, larger, controlled studies are needed to ascertain whether denosumab may play a role in malignant transformation of giant cell tumor of bone.http://dx.doi.org/10.1155/2015/767198 |
| spellingShingle | Cory Julian Broehm Erika L. Garbrecht Jeff Wood Therese Bocklage Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab Case Reports in Medicine |
| title | Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab |
| title_full | Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab |
| title_fullStr | Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab |
| title_full_unstemmed | Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab |
| title_short | Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab |
| title_sort | two cases of sarcoma arising in giant cell tumor of bone treated with denosumab |
| url | http://dx.doi.org/10.1155/2015/767198 |
| work_keys_str_mv | AT coryjulianbroehm twocasesofsarcomaarisingingiantcelltumorofbonetreatedwithdenosumab AT erikalgarbrecht twocasesofsarcomaarisingingiantcelltumorofbonetreatedwithdenosumab AT jeffwood twocasesofsarcomaarisingingiantcelltumorofbonetreatedwithdenosumab AT theresebocklage twocasesofsarcomaarisingingiantcelltumorofbonetreatedwithdenosumab |